Setting Priorities for Genomic Research.
Saved in:
| Title: | Setting Priorities for Genomic Research. |
|---|---|
| Authors: | Berrettini, Wade, Bierut, Laura, Crowley, Thomas J., Cubells, Joseph F., Frascella, Joseph, Gelernter, Joel, Hewttt, John K., Kreek, Mary Jeanne, Lachman, Herb, Leppert, Mark, Li, Ming D., Madden, Pamela, Miner, Cindy, Pollock, Jonathan D., Pomerleau, Ovide, Rice, John P., Rutter, Joni L, Shurtleff, David, Swan, Gary E., Tischfeld, Jay A. |
| Source: | Science (pre-March 2025). 6/4/2004, Vol. 304 Issue 5676, p1445-1446. 2p. |
| Subjects: | Genomics, Genetic disorders, Substance abuse, Vaccines, Opioid receptors, Polymorphism (Zoology) |
| Abstract: | K. R. Merikangas and N. Risen propose that diseases appearing to be highly amenable to environmental modification should take low priority in genomic research. Their conclusions ignore the large public health burden of complex genetic diseases like alcohol, nicotine and other substance abuse disorders, which cost society over $500 billion per year. Twin studies consistently show that genetic contributions for substance dependence account for half the disease variance. The A118G μ-opioid receptor polymorphism shows a preliminary association with therapeutic response to naltrexone treatment for alcoholism, implicating targeted treatment for alcoholics carrying 118G. |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | K. R. Merikangas and N. Risen propose that diseases appearing to be highly amenable to environmental modification should take low priority in genomic research. Their conclusions ignore the large public health burden of complex genetic diseases like alcohol, nicotine and other substance abuse disorders, which cost society over $500 billion per year. Twin studies consistently show that genetic contributions for substance dependence account for half the disease variance. The A118G μ-opioid receptor polymorphism shows a preliminary association with therapeutic response to naltrexone treatment for alcoholism, implicating targeted treatment for alcoholics carrying 118G. |
|---|---|
| ISSN: | 00368075 |
| DOI: | 10.1126/science.304.5676.1445c |
